Tyra Biosciences is expected to report a Q3 2026 loss of $0.67 per share on zero revenue, with the current stock price of $21.52 trading significantly below the $47.45 average analyst price target. Investors are primarily focused on clinical progression updates for dabogratinib (formerly TYRA-300), particularly data readouts from the SURF302 Phase 2 trial in non-muscle invasive bladder cancer.
Recent momentum has been fueled by the company's "dabogratinib 3x3" strategy, which aims to address multiple FGFR3-driven conditions including oncology and achondroplasia. However, rising research and development costs associated with these concurrent trials continue to widen net losses, making management’s commentary on the sustainability of its $383 million cash runway a critical priority for shareholders this quarter.